Early Trial Discontinuation in Toxicity-Driven, Dose-Escalating, Phase I Cancer Trials: Occurrence, Outcomes and Predictive Factors-Reference-Cited by-同舟云学术

Early Trial Discontinuation in Toxicity-Driven, Dose-Escalating, Phase I Cancer Trials: Occurrence, Outcomes and Predictive Factors

Published:2015-10-20 Issue:1 Volume:30 Page:49-55
ISSN:1178-2595
Container-title:Pharmaceutical Medicine
language:en
Short-container-title:Pharm Med

Author:

Cousin Sophie,Cassier Philippe A.,Gomez-Roca Carlos,Isambert Nicolas,Kotecki-Borghesi Nuria,Zanetta Sylvie,Tassy Louis,Simonet-Lamm Anne-Laure,De Maio Eleonora,Terret Catherine,Bouchet Juliette,Delord Jean-Pierre,Penel Nicolas

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40290-015-0120-8.pdf

Reference16 articles.

1. Olmos D, A’Hern RP, Marsoni S, Morales R, Gomez-Roca C, Verweij J, et al. Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. J Clin Oncol. 2012;30:996–1004.

2. Ploquin A, Olmos D, Ferté C, Cassier PA, Kramar A, Duhamel A, et al. Life-expectancy of patients enrolled in phase 1 clinical trials: a systematic review of published prognostic models. Crit Rev Oncol Hematol. 2012;83:242–8.

3. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809–19.

4. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–703.

5. Rodón J, Saura C, Dienstmann R, Vivancos A, Ramón y Cajal S, Baselga J, et al. Molecular prescreening to select patient population in early clinical trials. Nat Rev Clin Oncol. 2010;9:359–66.